The demonstration that extracts of gastrointestinal tissue [1] and blood [2] are associated with a glucagon-like ability to activate hepatic adenylate cyclase and to promote hyperglycaemia predates the radioimmunoassay era. The main upsurge in interest in substances related to glucagon is, however, a consequence of the development of routine radioimmunoassays for the hormone [3] . It has become apparent, as more laboratories engage in studies, that there is a lack of commonly accepted terminology to describe the glucagon-like polypeptides. Confusion regarding their relationship to glucagon has meant that much of the published work relating to these substances is unintelligible to the general scientific reader and not infrequently to other specialists in the field. In this article, it is proposed to give a brief account of the physicochemical and biological properties of the glucagon-like polypeptides in tissues and plasma, to assess their importance in physiology and to examine their structural and biosynthetic relationship to glucagon. In the course of this, a standard nomenclature will be proposed.
As radioimmunoassays for glucagon became more sophisticated [4] , it became apparent that the immunoreactive material present in extracts of mammalian gut and released by the gut in response to a glucose load was immunochemically distinct from glucagon. One group of antibodies raised against glucagon reacted strongly with materials of enteric and pancreatic origin but a second group of antibodies reacted only very weakly with material from the gut. Initially, the former group of antibodies were described as "cross-reactive" or "non-specific" and the latter group as "pancreatic glucagon specific" but, following the work of Senyk et al. [5] , Assan and Slusher [6] showed that "non-specific" antibodies were directed against an immunodeterminant in the amino-terminal and central portion of the glucagon molecule (amino acid residues ). The immunodeterminant for "specific" antibodies was located towards carboxyl-terminal region of the molecule (residues [24] [25] [26] [27] [28] [29] ). The terms "N-terminal specific" and "C-terminal specific", applied to antiglucagon sera, have now superceded the original classification. In this light, an empirical terminology to describe the glucagon-like polypeptides has been proposed by the nomenclature committee of the International Glucagon Symposium, Dallas, USA (1976) [7] but, regretably, the recommendations of the committee have not been universally adopted. It was proposed that the glucagon-like polypeptides are to be classified on the basis of their reactivity towards antibodies of known regional specificity. Irrespective of their tissue of origin, polypeptides which react with both C-and N-terminal specific antibodies are termed "Immunoreactive glucagon, IRG" and polypeptides which react only with N-terminal specific antibodies are termed "Glucagon-like immunoreactitity, GLI". The approximate molecular weight of a component is given as a superscript, e. g. IRG 35~176
The glucagon-like polypeptides in tissue extracts and plasma can be separated on the basis of molecular size and charge into multiple molecular forms. In addition to glucagon, pancreatic tissue extracts contain an acidic (pI = 4~ IRG component of approximate molecular weight of 9000, together with immunoreactive materials of smaller molecular size than glucagon which may represent degradation products [8] . A similar distribution of molecular forms is found in extracts of canine stomach [8] but evidence for the existence of appreciable quantities of gastric glucagon-like material in man is lacking. GLI components with approximate molecular weights of 12000 and 8000 and with isoelectric points in the range 6-8 represent the predominant immunoreactive forms in gut extracts [9, 10] , but a smaller (MW ~ 4500), 0012-186X/80/0018/0085/$01.00 basic (pI i> 9.5) GLI in the gut has also been identified by a number of workers [11, 12] . It is an oversimplification, however, to identify IRG exclusively with the pancreas and GLI exclusively with the gut. The presence of GLI components in the pancreas [13] and IRG components in the gut [14] has been demonstrated both by radioimmunoassay and immunohistochemical techniques. Glucagon-like polypeptides have recently been detected in the central nervous system of the dog [15] and rat [16] and are found in high concentrations in the salivary glands of rodents [17] . The IRG 9~176176 [8] , GL112~176176 [9] and GLI a~176176 [9] components are probably devoid of glucagon-like biological effects on metabolism but the GLI 4s~176 component has been shown to bind to receptor sites specific for glucagon in hepatic plasma membranes [11] , to activate hepatic adenylate cyclase [11] and to stimulate glycogenolysis [12] , although with a potency less than that of glucagon.
Considerable problems are associated with the measurement and characterisation of the glucagonlike polypeptides in plasma. IRG components of approximate molecular weight 9000, 3500 and 2000, corresponding to the" forms in tissue extracts, also circulate in plasma [18] but immunoreactivity, which can comprise up to 100% of the total, is also detected in the gamma-globulin (MW ~ 160000) fraction of plasma [19] . This poorly characterised component was initially described as an "interference factor" in radioimmunoassays [20] but is now generally referred to as "Big Plasma Glucagon, BPG". In the absence of conclusive experimental evidence, it has been proposed that BPG represents 1) a biosynthetic precursor of glucagon which is released into the circulation 2) a component which possesses sufficient homology with glucagon to be able to interfere specifically in radioimmunoassays by competing for antibody binding sites, 3) a component which interferes non-specifically in radioimmunoassays by interacting with antibody thereby blocking binding sites, 4) an artifact arising from degradation of the radiolabelled tracer and 5) glucagon or degradation products of glucagon bound to plasma components. At the present time there is no indication that BPG is important in metabolism.
The presence of GLI in blood was first suggested by Samols et al. [4] but the molecular forms of the circulating GLI components have not been adequately characterised. Plasma GLI concentrations are routinely determined by subtracting the level of immunoreactivity measured with a C-terminal specific antiserum from the level measured with an N-terminal specific antiserum. The precise significance of this difference in molecular terms is unclear. In view of the marked physicochemical and biological heterogeneity of the IRG and GLI components, it is difficult to correlate changes in the levels of plasma immunoreactivity with physiological events. Similarly, the rapid proteolytic degradation of the glucagon-like polypeptides in plasma results in the circulation of multiple immunoreactive, but biologically inactive, C-and N-terminal fragments of glucagon so that the assumption that an N-terminal specific antiserum measures total immunoreactivity is inaccurate. It follows that terms such as the "enteroglucagon" response to a particular stimulus can be misleading unless it is made clear, in molecular terms, exactly what has been measured in the assays.
At the present time, there is insufficient evidence to assign a biological role to the glucagon-like polypeptides. Although hypotheses have been presented linking gut GLI with enterogastrone activity [21] , inhibition of gastrointestinal motility [22] , atrophic effect upon gut mucosa [22] , anti-lipolytic activity [23] and inhibitory effects upon glucagon-induced glycogenolysis [24] and insulin-induced hepatic glucose uptake [25] , conclusive evidence in support of these hypotheses is required. Indeed, it has been suggested [26] that the gut GLIs may simply represent a primitive peptide family from which the structurally related and biological active hormones glucagon, secretin, VIP and GIP may have evolved but that specialised biological activity is manifested only by the descendant polypeptides. Nevertheless, firm evidence linking the GL145~176 component from the gut with glucagon-like biological activity has been provided and this component may play a role in carbohydrate metabolism. Pancreatectomised man has been proposed as a model for diabetes without glucagon [27] but it has been pointed out [28] that the GL145~176 component, undetectable with C-terminal specific antibodies, probably circulates in pancreatectomised man and may be important in promoting hyperglycaemia. Consequently, the assertion that insulin-lack is the only factor responsible for the abnormalities of carbohydrate metabolism in these subjects requires further examination.
In recent years, a number of studies have provided firm evidence that all the glucagon-like polypeptides of the pancreas and gut share a common biosynthetic pathway and may be derived from a common precursor molecule. A 100 amino acid polypeptide, glicentin, has been isolated from porcine gut and shown to contain the full sequence of glucagon, extended from the N-terminus by 63 amino acids and from the C-terminus by a basic 8 amino acid chain [29, 30] . A basic 4500 dalton GLI component, isolated from bovine/porcine pancreas was similarly shown to contain the full sequence of glucagon extended from the C-terminus by the same 8 amino . Furthermore, immunofluorescence studies, using an antiserum raised against glicentin that does not bind glucagon, have shown the presence of the glicentin immunodeterminant in the A cells of the pancreas [32] and stomach [33] as well as in the L cells of the gut [32, 33] . These and related studies [10] have provided evidence for the proposed structures of the predominant molecular forms of the glucagon-like polypeptides which are shown in Figure 1 . IRG components represent the full sequence of glucagon extended from the N-terminus only so that the C-terminal immunodeterminant of glucagon is accessible to antibodies. GLI components also contain the full sequence of glucagon but are extended from the Cterminus as well so that the C-terminal immunodeterminant of glucagon is now inaccessible to antibodies. Progressive shortening of the N-terminal extension to the glucagon sequence in the common precursor of the glucagon-like polypeptides, without removal of the C-terminal extension, gives rise to the GLI components which predominate in the intestine. In contrast, removal of the C-terminal extension to the glucagon sequence, at some stage in the biosynthetic pathway, gives rise to the series of IRG components which predominate in the pancreas. It can be seen from Figure 1 that glucagon-like biological activity is manifested only by those polypeptides that lack an N-terminal extension to the glucagon sequence. Conflicting reports from a number of laboratories, involving incorporation of radiolabelled amino acids into islet tissue from a variety of species, have suggested a molecular weight of between 12 000 and 69 000 for the biosynthetic precursor. In a recent study [34] , analysis of newly synthesis proteins from rat islets has identified an 18,000 dalton polypeptide as proglucagon which was converted, under pulsechase conditions into immunoreactive polypeptides with molecular weights of 13 000, 4500 and 3500.
The concept that post-translational modifications of a single primary gene product can generate a family of structurally related polypeptides is well established in endocrinology. For example, the lipotropins, endorphins, melanotropins, corticotrophin and met-enkephalin probably derive from a single 31000 dalton precursor, pro-opiocortin [35] . It is clear, therefore, that the different distribution of the glucagon-like polypeptides in tissues is not due to a difference in the primary gene product of the endocrine cells in those tissues. It is a consequence of the different processing of a single product by proteolytic enzymes in the cells.
The author hopes that this article has gone some way in removing the study of the glucagon-like polypeptide from the realm of esoteric lore and placing it in the mainstream of polypeptide endocrinology. It is not suggested that the terminology used in this article represents the "final" classification. Nevertheless, workers are urged to compromise their rigidly held views regarding nomenclature in order to achieve a greater measure of linguistic uniformity from which a clearer understanding may develop.
